Skip to content
DataLookout
Menu

NCT04446650

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Trial completed
    • Study completion date changed from estimate of Nov 30, 2026 to Oct 16, 2026
    • Secondary endpoints: details revised at 3 of 14 entries
  2. Notable Lead sponsor: Celgene to Bristol-Myers Squibb
    • Study completion date: Oct 31, 2025 to Nov 30, 2026
    • Site details revised at 1 of 21 sites
    v13
  3. Minor Study completion date: Jun 30, 2025 to Oct 31, 2025
    • Site details revised at 1 of 21 sites
    v12
  4. Minor Primary completion date changed from estimate of Oct 2, 2023 to Oct 5, 2023v11
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 21
    • Primary completion date: Nov 29, 2023 to Oct 2, 2023
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary completion date: Mar 17, 2023 to Nov 29, 2023
    • Site details revised at 1 of 22 sites
    v8
  2. Minor Study sites: 26 to 22v7
  3. Minor Study sites: 25 to 26v6
  4. Minor Study sites: 16 to 25v5
  5. Minor Primary completion date: Nov 5, 2022 to Mar 17, 2023
    • Study completion date: Dec 31, 2024 to Jun 30, 2025
    • Site details revised at 2 of 16 sites
    v4
  6. Notable Eligibility criteria expanded, about 47 words
    • Site details revised at 1 of 16 sites
    v3
  7. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Jun 30, 2020 to Oct 12, 2020
    • Study sites: 0 to 16
    • Primary completion date: Jul 6, 2022 to Nov 5, 2022
    • Study completion date: Jul 31, 2024 to Dec 31, 2024
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (MTD)
Timeframe: Up to Cycle 1 (each cycle is 28 days)
Recommended Phase 2 dose (RP2D)
Timeframe: Up to Cycle 1 (each cycle is 28 days)
Response Rate (RR)
Timeframe: Up to Cycle 6 (each cycle is 28 days)

Secondary (14)

Adverse Events (AEs)
Pharmacokinetics - Cmax
Pharmacokinetics - AUC
Pharmacokinetics - Tmax
Symptom response rate (SRR)
Show 9 moreShow less
Spleen volume response rate 25 (RR25)
Spleen Response Rate by Palpation (RRP)
Duration of spleen volume response (DR)
Duration of spleen response by palpation (DRP)
Duration of symptoms response (DSR)
Spleen and Disease Progression Free Survival (SDPFS)
Gastrointestinal adverse events
Wernicke encephalopathy (WE) events
Overall Survival (OS)

Arms and interventions

Fedratinib AdministrationExperimental

The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.

Drugs: Fedratinib

Sites

21 sites in 1 country